unknown
Open source record Compound Directory
MOTS c
A reviewed compound profile linking technical facts, evidence summaries, limitations, studies, trials, COAs, and related products.
Reviewed sources
Clickable primary records and approved journal metadata.
pubmed
MOTS-c Functionally Prevents Metabolic Disorders.
Yue Gao, Xinran Wei, Pingying Wei, Huijie Lu, Luying Zhong, Jie Tan, Hongbo Liu, Zheng Liu · Metabolites · 2023
Review
Open source recordpubmed
The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.
Yadong Yin, Yihui Pan, Jin He, Hong Zhong, Yangyang Wu, Chenbo Ji, Lan Liu, Xianwei Cui · Pharmacological research · 2022
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Role of MOTS-c in the regulation of bone metabolism.
Xuejie Yi, Guangxuan Hu, Yang Yang, Jing Li, Junjie Jin, Bo Chang · Frontiers in physiology · 2023
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.
Wei Wan, Lieliang Zhang, Yue Lin, Xiuqing Rao, Xifeng Wang, Fuzhou Hua, Jun Ying · Journal of translational medicine · 2023
Review
Open source recordpubmed
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury.
Zihao Shen, Peng Lu, Wanjun Jin, Ziang Wen, Yuanpu Qi, Xiangyu Li, Mingyu Chu, Xin Yao, Minchao Wu, Ao Wang, Xiao Zhang, Wei Wang, Meijuan Song, Xiaowei Wang · American journal of respiratory cell and molecular biology · 2025
Preclinical animal study · Human participants; verify the population in the source
Open source recordVerified COA records
Only approved public COAs matched to this product, strength, lot, and batch are shown.
historical · Lot FFH-MS10-01
10mg
ILS Laboratories LLC · COA-2026--MJ1GE · 2026-08-03
Registered trials
NCT07505745 · RECRUITING
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.
Outcomes: Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index) · Incidence of treatment-emergent adverse events (TEAEs) · Change from baseline in HbA1c. · Change from baseline in fasting glucose · Change from baseline in 2-hour plasma glucose during 75 g OGTT. · Immunogenicity (anti-drug antibodies, if applicable).
PHASE2
NCT04027712 · UNKNOWN
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease
Outcomes: mots-c predicts cardiovascular mortality in diabetic with coronary artery disease · b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease · b amyloid predicts cardiovascular mortality in diabetic with coronary artery
NCT07678073 · RECRUITING
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated. This prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis. The primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.
Outcomes: Serum ferroptosis-related biomarkers (Fe, TFRC1, GPX4, MDA, ACSL4) and mitochondrial-derived peptides (humanin and MOTS-c) · Delayed Graft Function (DGF) · Postoperative Serum Creatinine Levels · Requirement for Postoperative Dialysis · Urine Output · Length of Hospital Stay · Association Between Biomarkers and Clinical Outcomes
NA